We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lyophilized Control Monitors Precision of Tumor Marker Testing

By LabMedica International staff writers
Posted on 12 Feb 2009
A lyophilized quality control based on human serum, monitors the precision of tumor marker testing procedures.

The Lyphochek tumor marker plus control includes high target levels of cancer antigens and ferritin, as well as a very low level of prostate-specific antigen (PSA). It has a three-year shelf life when stored at 2-8 ºC. Its reconstituted stability is 14 days at 2-8 ºC and 30 days at -20-70 °C (for most analytes).

Assayed values are provided for manual and automated test methods. The Unity Interlaboratory Program with peer group comparison is available for use with the Lyphochek tumor marker plus control. The Unity Interlaboratory Program is an expert data management software system designed to improve the effectiveness of quality control processes.

Launched by Bio-Rad Laboratories, (Hercules, CA, USA), a multinational manufacturer and distributor of clinical diagnostic products, the Lyphochek multianalyte control features 23 tumor markers. Being a blood-based material, the control can be processed in the same manner as patient samples, ensuring quality on an ongoing basis.

Bio-Rad products are used worldwide by laboratories, hospitals, universities, major research institutions, as well as biotechnology and pharmaceutic companies.

Related Links:

Bio-Rad Laboratories




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics

Latest Immunology News

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
12 Feb 2009  |   Immunology

Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
12 Feb 2009  |   Immunology

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
12 Feb 2009  |   Immunology